Leerink Partnrs Issues Negative Estimate for A Earnings

Agilent Technologies, Inc. (NYSE:A) – Analysts at Leerink Partnrs dropped their Q1 2025 EPS estimates for Agilent Technologies in a report issued on Tuesday, November 26th. Leerink Partnrs analyst P. Souda now forecasts that the medical research company will post earnings per share of $1.28 for the quarter, down from their prior estimate of $1.36. The consensus estimate for Agilent Technologies’ current full-year earnings is $5.72 per share. Leerink Partnrs also issued estimates for Agilent Technologies’ Q2 2025 earnings at $1.33 EPS, Q3 2025 earnings at $1.41 EPS, Q4 2025 earnings at $1.55 EPS, FY2025 earnings at $5.57 EPS and FY2026 earnings at $6.10 EPS.

A number of other equities analysts also recently issued reports on A. TD Cowen increased their price objective on shares of Agilent Technologies from $153.00 to $160.00 and gave the company a “buy” rating in a research note on Thursday, August 22nd. Barclays dropped their price objective on shares of Agilent Technologies from $145.00 to $135.00 and set an “underweight” rating on the stock in a research note on Wednesday. Stifel Nicolaus reissued a “buy” rating and set a $151.00 target price on shares of Agilent Technologies in a research report on Monday, August 26th. Evercore ISI increased their target price on shares of Agilent Technologies from $135.00 to $145.00 and gave the company an “in-line” rating in a research report on Tuesday, October 1st. Finally, Sanford C. Bernstein decreased their target price on shares of Agilent Technologies from $140.00 to $135.00 and set a “market perform” rating for the company in a research report on Tuesday. One analyst has rated the stock with a sell rating, seven have given a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $143.40.

Agilent Technologies Price Performance

NYSE A opened at $138.14 on Wednesday. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.37 and a current ratio of 1.78. The firm’s 50 day moving average price is $137.65 and its 200-day moving average price is $137.44. Agilent Technologies has a 52-week low of $124.10 and a 52-week high of $155.35. The company has a market cap of $39.69 billion, a PE ratio of 28.66, a P/E/G ratio of 5.91 and a beta of 1.07.

Agilent Technologies Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, January 22nd. Investors of record on Tuesday, December 31st will be issued a dividend of $0.248 per share. This represents a $0.99 annualized dividend and a dividend yield of 0.72%. The ex-dividend date of this dividend is Tuesday, December 31st. This is a boost from Agilent Technologies’s previous quarterly dividend of $0.24. Agilent Technologies’s dividend payout ratio (DPR) is 20.54%.

Insider Buying and Selling

In related news, SVP Dominique Grau sold 9,990 shares of the firm’s stock in a transaction on Thursday, September 26th. The shares were sold at an average price of $145.00, for a total transaction of $1,448,550.00. Following the sale, the senior vice president now owns 40,011 shares in the company, valued at approximately $5,801,595. This trade represents a 19.98 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.33% of the stock is currently owned by corporate insiders.

Institutional Trading of Agilent Technologies

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Massachusetts Financial Services Co. MA grew its position in shares of Agilent Technologies by 5.7% in the second quarter. Massachusetts Financial Services Co. MA now owns 15,064,660 shares of the medical research company’s stock valued at $1,952,832,000 after purchasing an additional 809,149 shares during the period. FMR LLC grew its position in shares of Agilent Technologies by 62.2% in the third quarter. FMR LLC now owns 1,287,665 shares of the medical research company’s stock valued at $191,193,000 after purchasing an additional 493,947 shares during the period. Worldquant Millennium Advisors LLC acquired a new stake in shares of Agilent Technologies in the third quarter valued at about $49,449,000. Marshall Wace LLP grew its position in shares of Agilent Technologies by 48.6% in the second quarter. Marshall Wace LLP now owns 957,128 shares of the medical research company’s stock valued at $124,073,000 after purchasing an additional 313,155 shares during the period. Finally, Jennison Associates LLC grew its position in shares of Agilent Technologies by 63.3% in the third quarter. Jennison Associates LLC now owns 586,439 shares of the medical research company’s stock valued at $87,075,000 after purchasing an additional 227,431 shares during the period. Institutional investors and hedge funds own 87.42% of the company’s stock.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.